Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations.

ABSTRACT:

Importance

Patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/2 alterations are eligible to receive poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors as single agents or in combination with an androgen receptor pathway inhibitor after these agents showed survival improvement in their landmark clinical trials. However, data are limited regarding the uptake of PARP inhibitors in these patients.

Objective

To investigate the use of PARP inhibitors in patients with mCRPC harboring BRCA1/2 alterations.

Design, setting, and participants

This retrospective cohort study used the deidentified Flatiron-Health electronic health record-derived database of US community and academic practices to extract patient-level data. The data cu

SUBMITTER: Ostrowski M 

PROVIDER: S-EPMC12492053 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature